Frazier Healthcare Partners Revenue and Competitors

Seattle, WA USA

Location

$9.7B

Total Funding

VC/PE

Industry

Estimated Revenue & Valuation

  • Frazier Healthcare Partners's estimated annual revenue is currently $15M per year.(i)
  • Frazier Healthcare Partners received $377.0M in venture funding in October 2013.
  • Frazier Healthcare Partners's estimated revenue per employee is $140,187
  • Frazier Healthcare Partners's total funding is $9.7B.

Employee Data

  • Frazier Healthcare Partners has 107 Employees.(i)
  • Frazier Healthcare Partners grew their employee count by 2% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7.5M333%$2BN/A
#2
$15M1072%$9.7BN/A
#3
$15M9924%$19.3MN/A
#4
N/A25-4%N/AN/A
#5
N/A15-59%N/AN/A
#6
$15M15-6%$100.1MN/A
#7
$3.5M584%N/AN/A
#8
N/A160%N/AN/A
#9
N/A4164%N/AN/A
#10
N/A11-21%N/AN/A
Add Company

Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $3.0 billion total capital raised, Frazier has invested in over 170 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm's Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe. For more information about Frazier Healthcare Partners, visit the company's website at http://www.frazierhealthcare.com.

keywords:Finance,Healthcare,Human Resources Hr,Pharmaceuticals

$9.7B

Total Funding

107

Number of Employees

$15M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Frazier Healthcare Partners News

2022-04-19 - Boston developer of norovirus vaccine plans $175M IPO ...

HilleVax was a collaboration between Takeda and Frazier Healthcare Partners. The vaccine, HIL-214, is now in midstage development.

2022-04-19 - HilleVax Sets IPO at 10.3 Million Shares; Sees Pricing at $16 ...

Takeda Pharmaceutical Co. and private-equity firm Frazier Healthcare Partners last year formed HilleVax to develop and commercialize...

2022-03-30 - HilleVax, a Biopharma Developing Vaccines, Is Going Public

HilleVax, which was formed by Takeda Pharmaceutical and private-equity firm Frazier Healthcare Partners, is going public.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15.5M1074%N/A
#2
$37.8M10726%N/A
#3
$16.8M1071%$16M
#4
$23.5M107-9%N/A
#5
$23.5M1078%N/A

Frazier Healthcare Partners Funding

DateAmountRoundLead InvestorsReference
2013-10-02$377.0MSeventhArticle